BridgeMD
Antiviral treatment for long covid.
EU CTIS ID: 2023-510337-29-00
What this study is testing
The primary objective is to invesigate if early treatment with Paxlovid (nirmatrelvir plus ritonavir) for patients with acute COVID (confirmed PCR or lateral flow test) can reduce long term complications (long COVID)
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Symptoms attributable to COVID-19 started within the past 5 days and ongoing.
- Positive PCR or lateral flow SARS-CoV-2 test. Any positive PCR test or a lateral flow test taken between two days before symptom onset and randomisation qualifies.
- Age between 18 and 65 years.
- Participant is able and willing to provide informed consent.
- Willingness to take a pregnancy test prior to starting study treatment (Participants of childbearing potential).
You likely can't join if
- Patients that are not able to provide informed consent or comply with all study visits.
- Use of concomitant medication contraindicated for the treatment of Paxlovid.
- Pregnant and lactating woman.
- Participants of childbearing potential (participants who are anatomically and psysiologically capable of becoming pregnant), or have a partner of childbearing potential, not willing to use highly effective contraceptive until 7 days after completing Paxlovid.
- Patient currently inpatient at hospital.
- Comorbidity which requires active antiviral treatment as judged by the investigator.
See the full eligibility criteria
- Symptoms attributable to COVID-19 started within the past 5 days and ongoing.
- Positive PCR or lateral flow SARS-CoV-2 test. Any positive PCR test or a lateral flow test taken between two days before symptom onset and randomisation qualifies.
- Age between 18 and 65 years.
- Participant is able and willing to provide informed consent.
- Willingness to take a pregnancy test prior to starting study treatment (Participants of childbearing potential).
- Patients that are not able to provide informed consent or comply with all study visits.
- Use of concomitant medication contraindicated for the treatment of Paxlovid.
- Pregnant and lactating woman.
- Participants of childbearing potential (participants who are anatomically and psysiologically capable of becoming pregnant), or have a partner of childbearing potential, not willing to use highly effective contraceptive until 7 days after completing Paxlovid.
- Patient currently inpatient at hospital.
- Comorbidity which requires active antiviral treatment as judged by the investigator.
- Any chronic renal impairment.
- Any chronic liver disease or liver impairment.
- Previous randomisation in the PANORAMIC Norway trial.
- Currently participating in a clinical trial of a therapeutic agent.
- Currently taking Paxlovid.
- Known allergy to Paxlovid.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.